Private equity

What Novo Holdings’ Asia head wants from CVs

The investment manager for Denmark’s Novo Nordisk Foundation put capital into a private equity continuation fund in Asia last year alongside KKR, Amit Kakar tells Secondaries Investor.

New and old faces

Hollyport Capital has chosen to remain independent, accepting the backing of Blue Owl in a move that reflects how the industry’s growth is likely to be fuelled.

Korea’s NPS adds another $1bn of secondaries exposure

The pension’s secondary funds and co-investments grew 36% to approximately $3.7bn, per its latest investment disclosure.

Hollyport maintains independence with stake sale to Blue Owl

Blue Owl has acquired a passive stake in the tail-end specialist, which will ‘ultimately represent’ approximately 25% of the economic interests of the firm.

Apollo, Pantheon and SQ Capital co-lead on Exponent’s €750m CV

The transaction values engineering services company H&MV at €1.4bn.

StepStone surpasses $20bn in private wealth AUM

Four of the firm’s cornerstone evergreen products are heavily weighted to secondaries investments.

MetLife closes $1.2bn managed fund deal with Lexington

The insurer had shopped a portfolio of funds and co-investments with a net asset value of $1.8bn, Secondaries Investor understands.

KKR and Arctos mull GP-led strategy launch

KKR believes it can build a ‘world-class’ business targeting the sub-segment, CFO Robert Lewin said on the firm’s Q2 2026 earnings call.

The shorter the hold, the higher the burden

Assessing a quick-flip continuation vehicle on the asset’s hold period alone is an imperfect metric.

CVC aims for Q3 close for 6th secondaries fund

The firm, which is also planning to launch its first infra secondaries vehicle, has raised $9.3bn to date for Fund VI, according to its H1 2026 results.